FATE - Company ID 0001434316
The table below shows FATE THERAPEUTICS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$30.82M | -$33.81M | -$33.35M | -$28.86M | -$64.61M | -$27.10M |
| Capital expenditure | $239.00K | $1.20M | $86.00K | $3.21M | $10.08M | $3.98M |
| Investing cash flow | $23.59M | $42.67M | $17.31M | $9.34M | -$7.03M | -$471.89M |
| Dividends paid | - | - | - | - |
FATE THERAPEUTICS INC reported operating cash flow of -$106.08M for fiscal year 2025. That is up 13.7% from -$122.87M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$29.82M (FY 2016) to -$106.08M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | $0.00 | $95.49M | $207.00K | $2.80M | $438.05M |